Scientists test new Two-Drug attack on tough cancers
NCT ID NCT03905148
Summary
This early-stage study tested the safety and initial effects of combining two oral drugs, BGB-283 and PD-0325901, in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug combination could shrink tumors. The study involved 91 participants with various cancers, including lung, colorectal, ovarian, and melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, 2148, Australia
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
MD Anderson
Houston, Texas, 77030, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
The Prince of Wales Private Hospital - Specialist Medical Randwick
Randwick, New South Wales, 2031, Australia
-
University of California Los Angeles
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.